NEW YORK (GenomeWeb) – Great Basin said today that it has received 510(k) clearance from the US Food and Drug Administration for its stool bacterial pathogens panel, which "addresses a significant unmet need" for an affordable panel that quickly and accurately diagnoses patients suffering from food-borne gastrointestinal distress.

Great Basin noted that its assay simultaneously detects Salmonella, Shigella, Shiga Toxin-producing E. coli, and Campylobacter — bacterial pathogens that make up nearly 95 percent of all food-borne illnesses in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.